Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
The association between HOXA4 and lung adenocarcinoma is presently supported by a study of 36 young never‑smoker Chinese patients diagnosed with lung adenocarcinoma (PMID:29667179). In this cohort, HOXA4 was identified as one of several rarely reported candidate mutations through whole genome sequencing, suggesting a potential but preliminary role in the disease’s heterogeneous genetic landscape.
Although functional studies have investigated HOXA4 in cardiac contexts – notably in myocardial infarction and heart failure models (PMID:35000421) – no lung adenocarcinoma‑specific functional assessments have yet been reported. Overall, the genetic evidence remains limited, and further replication studies with segregation and functional validation are necessary to firmly establish the clinical utility of HOXA4 as a marker for lung adenocarcinoma.
Gene–Disease AssociationLimitedThe association is based on a single cohort of 36 young never‑smoker patients with lung adenocarcinoma, with HOXA4 identified as a rare candidate mutation and lacking familial segregation or replication studies (PMID:29667179). Genetic EvidenceLimitedThe genetic evidence comprises identification of HOXA4 as a rarely reported candidate mutation in whole genome sequencing data of lung adenocarcinoma patients, without detailed variant-level data or segregation analysis. Functional EvidenceLimitedWhile functional studies in cardiac models have explored HOXA4 activity, no lung adenocarcinoma‑specific experimental evidence is currently available to support its pathogenic role in this context. |